ClinicalTrials.gg

Carcinoma, Neuroendocrine clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 172 studies for Carcinoma, Neuroendocrine across more than 10 countries. 66 are recruiting or about to start. 112 of them are mainly about Carcinoma, Neuroendocrine (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 4 narrower conditions too, such as Carcinoma, Merkel Cell: 498 studies, 135 open.

Status

Completed
56
Recruiting
47
Active, not recruiting
19
Status unknown
18
Not yet recruiting
15
Terminated
8

Phase

Phase 2
110
Phase 1
44
Phase 3
8
Phase 4
1

Where

United States
73
China
39
Italy
18
France
17
Canada
10
Spain
10

Who develops what

Add Carcinoma, Neuroendocrine to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 13 programs from 12 companies, 6 with this as their studies’ main aim; 4 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Suzhou Zelgen Biopharmaceuticals, Hansoh Pharmaceutical Group and Qilu Pharmaceutical here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
EtoposideRecent, repeated
Evidence
  • NCT07833839 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3 · live · background · “Etoposide Injection” · registered Sep 2026
  • NCT07720193 · Nanjing Leads Biolabs Co.,Ltd · Phase 3 · live · background · “Etoposide injection” · registered Jul 2026
  • NCT06372626 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2 · live · background · “Etoposide” · registered Apr 2024
  • NCT06157827 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · background · “Etoposide Injection” · registered Nov 2023
  • NCT05652686 · Phanes Therapeutics · Phase 2 · live · background · “Carboplatin + Etoposide” · registered Dec 2022
Hoffmann-La Roche14% of its industry studiesUS: off-patent, 5 generics marketed35 studies
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07720193 · Nanjing Leads Biolabs Co.,Ltd · Phase 3 · live · background · “Carboplatin injection” · registered Jul 2026
  • NCT07174583 · IDEAYA Biosciences · Phase 2 · live · background · “Carboplatin” · registered Sep 2025
  • NCT06157827 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · background · “Carboplatin Injection” · registered Nov 2023
  • NCT05652686 · Phanes Therapeutics · Phase 2 · live · background · “Carboplatin + Etoposide” · registered Dec 2022
Eli Lilly and Company16% of its industry studies34 studies
IrinotecanRecent, repeated
Evidence
  • NCT07595913 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3 · live · comparator · “5-fluorouracil, Calcium folinate and Irinotecan” · registered May 2026
  • NCT05652686 · Phanes Therapeutics · Phase 2 · live · background · “Irinotecan (drug)” · registered Dec 2022
  • NCT05015621 · HUTCHMED · Phase 3 · live · comparator · “5-fluorouracil, Calcium folinate and Irinotecan” · registered Aug 2021
Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016)22 studies
CisplatinRecent, repeated
Evidence
  • NCT07833839 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3 · live · background · “Cisplatin Injection” · registered Sep 2026
  • NCT07720193 · Nanjing Leads Biolabs Co.,Ltd · Phase 3 · live · background · “Cisplatin injection” · registered Jul 2026
  • NCT06372626 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2 · live · background · “Cisplatin” · registered Apr 2024
  • NCT06157827 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · background · “Cisplatin injection” · registered Nov 2023
Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed24 studies

6 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Alveltamig☆ Track1 live phase-3 study: NCT07595913Suzhou Zelgen Biopharmaceuticals Co.,Ltd
QLC5508☆ Track1 live phase-3 study: NCT07894211Qilu Pharmaceutical Co., Ltd.
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024☆ Track1 live phase-3 study: NCT07720193Nanjing Leads Biolabs Co.,Ltd
nilvanstomig☆ Track1 live phase-3 study: NCT07833839Suzhou Zelgen Biopharmaceuticals Co.,Ltd

The 4 in phase 3 with the nearest primary completion, of 13 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 28 Dec 2026 est.Anti-PD-L1/4-1BB Bispecific Antibody LBL-024 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 main aim+ Etoposide Injection, Carboplatin Injection, Cisplatin injection vs atezolizumabadded to Etoposideadded to CarboplatinNCT06157827 A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma — primary endpoint: Objective Response Rate (ORR) · 178 enrolled
  • Apr 2027 est.Alveltamig · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2 named, not the main aimNCT06283719 Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer — primary endpoint: Objective response rate (ORR) · 265 enrolled
  • Aug 2027 est.SSTR2-targeting Non-peptide Drug Conjugate CRN09682 · Vertex Pharmaceuticals Incorporated · Phase 2 registry mapping onlyNCT07129252 A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors — primary endpoint: (Dose Escalation) Incidence and severity of DLTs. · 150 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Carcinoma, Neuroendocrine studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 9 open · Tyrosine kinase inhibitors (TKIs) 4 open · Antimetabolites 1 open · HDAC inhibitors 1 open · Alkylating agents 6

Coming up

23studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 47 Carcinoma, Neuroendocrine studies recruiting now, 30 (64%) set no upper age limit and 10 (21%) stop at 75 or younger. 2 (4%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 47
AgeWomenMen
101 (2%)1 (2%)
1845 (96%)45 (96%)
3047 (100%)47 (100%)
4046 (98%)46 (98%)
5046 (98%)46 (98%)
6546 (98%)46 (98%)
7544 (94%)44 (94%)
8535 (74%)35 (74%)

Across all 172 studies, recruiting or not: 13% stop at 75 or younger and 1% at 65; 8% take children; 1% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Carcinoma, Neuroendocrine studies take

Of 43 phase 2 interventional studies under Carcinoma, Neuroendocrine, half reached primary completion within 69 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 269 mo50–91 · 43 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 172. Browse all 172 → or search them.